Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 10/20 | 0.49 |
| ▸ | TDO2 | P48775 | 7/20 | 0.49 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | GSR | P00390 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 2/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1520935 | 1.00 | IDO1 (0.49) | IDO1TDO2TRPA1GSRHRH1 | |
| SCHEMBL1520937 | 1.00 | IDO1 (0.49) | IDO1TDO2TRPA1GSRHRH1 | |
| SCHEMBL1520614 | 0.88 | IDO1 (0.46) | IDO1TDO2TRPA1GSRHRH1 | |
| SCHEMBL18982890 | 0.83 | TRPA1 (0.47) | TRPA1GSRHRH1HTR2ATAAR1 | |
| SCHEMBL1521287 | 0.83 | GSR (0.53) | IDO1TDO2TRPA1GSRHTR2A | |
| SCHEMBL1520670 | 0.81 | HRH1 (0.58) | IDO1TDO2HRH1HTR2ATAAR1 | |
| SCHEMBL5799572 | 0.79 | IDO1 (0.49) | IDO1TDO2HRH1HTR2ATAAR1 | |
| SCHEMBL1832901 | 0.79 | TRPA1 (0.48) | TRPA1GSRHRH1HTR2ASLC6A4 | |
| SCHEMBL7090878 | 0.79 | TRPA1 (0.44) | TRPA1GSRHRH1HTR2ASLC6A4 | |
| SCHEMBL12530561 | 0.79 | TRPA1 (0.48) | TRPA1GSRHRH1HTR2ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130289083-A1 | IDO Inhibitors | NEWLINK GENETICS CORPORATION | 2013-10-31 | — | — | US | disclosed |
| EP-2227233-B1 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2013-02-13 | — | — | EP | disclosed |
| US-20110053941-A1 | IDO Inhibitors | NEWLINK GENETICS (US) | 2011-03-03 | — | — | US | disclosed |
| EP-2227233-A2 | IDO INHIBITORS | Newlink Genetics (US) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009073620-A2 | IDO INHIBITORS | NEWLINK GENETICS (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053941-A1 | IDO Inhibitors | IDO1, IDO2, INMT | IDO1 1/4885TDO2 4/4885TRPA1 4051/4885 |
| US-20130289083-A1 | IDO Inhibitors | IDO1, IDO2, INMT | IDO1 1/4885TDO2 4/4885TRPA1 3995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.